NovaBay Pharmaceuticals Inc. appointed Yanbin Liu as a director after the resignation of Xiaoyan Liu, effective March 21.

Xiaoyan Liu did not resign due to any disagreements on any matter relating to the company's operations, policies or practices, according to NovaBay.

Yanbin Liu, a non-independent board member, will takeover Xiaoyan Liu's place as a class III director to serve until the annual stockholders' meeting in 2019. He has served as the joint COO and head of direct investment of OP Financial Investments Ltd. in Hong Kong since February 2015.

OP Financial has a significant investment in NovaBay and Yanbin Liu was appointed as a representative of OP Financial.

Emeryville, Calif.-based NovaBay Pharmaceuticals is a pharmaceutical company that develops, manufactures and markets anti-infective products for the eye care market in the U.S.